|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
13 May 2013 |
|
Main ID: |
NCT00037518 |
|
Date of registration:
|
17/05/2002 |
|
Primary sponsor: |
|
|
Public title:
|
A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer
|
|
Scientific title:
|
An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism. |
|
Date of first enrolment:
|
April 2001 |
|
Target sample size:
|
46 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00037518 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Amgen |
| | |
|
Key inclusion & exclusion criteria
|
- Patients must have parathyroid carcinoma or severe primary hyperparathyroidism; *
Abnormally elevated calcium levels above 12.5 mg/dL; * Not be pregnant or nursing; *
Not have had any type of cancer other than parathyroid carcinoma within the last 5
years.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Hyperparathyroidism
|
|
Parathyroid Neoplasms
|
|
Intervention(s)
|
|
Drug: AMG 073
|
|
Primary Outcome(s)
|
|
Changes in serum calcium and PTH
|
|
Secondary Outcome(s)
|
|
Safety and tolerability of cinacalcet
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|